Ispecimen INC 8-K filings

iSpecimen Inc. has entered into a three-month consulting agreement for marketing and advertising services with IR Agency LLC for $2,000,000.

iSpecimen Inc. has entered into a settlement agreement with WestPark Capital, Inc. to resolve all disputes, including an ongoing arbitration, for a payment of $97,500.

iSpecimen Inc. has successfully closed a public offering of common stock and pre-funded warrants, raising approximately $5 million to fund liabilities, acquisitions, and working capital.

iSpecimen Inc. announced the completion of Milestone 3 in its digital transformation program, making a $700,000 payment for enhanced marketplace features and broader rollout.

iSpecimen Inc. has been notified by Nasdaq that it fails to meet the minimum stockholders' equity requirement for continued listing.

iSpecimen Inc. shareholders approved the election of a director, the appointment of auditors, and a new stock incentive plan.

iSpecimen Inc. has secured $2.5 million in gross proceeds through a private placement of common stock and pre-funded warrants.

iSpecimen Inc. has implemented a 1-for-40 reverse stock split to boost its share price and maintain Nasdaq listing compliance.

iSpecimen Inc. announced its 2025 Annual Meeting of Stockholders has been adjourned for the fifth time due to a lack of quorum, with the next reconvened meeting scheduled for May 8, 2026.

iSpecimen announces a new shipping model reducing human biospecimen transit times by up to 85% and lowering costs.

iSpecimen Inc. has repeatedly adjourned its 2025 Annual Meeting of Stockholders due to a persistent lack of quorum, with the meeting now rescheduled for April 10, 2026.

iSpecimen Inc. announced the immediate resignation of independent director Siyun Yang, effective February 17, 2026.

iSpecimen Inc. announced the successful completion of its digital transformation Milestone 2, activating its live production marketplace, alongside significant operational achievements in biospecimen procurement.

iSpecimen Inc. has again adjourned its 2025 Annual Meeting of Stockholders to February 13, 2026, as a quorum was not achieved.

iSpecimen Inc. has amended the terms of its Series C Convertible Non-Voting Preferred Stock to include proportionate adjustments for conversion and floor prices following stock splits or combinations.

iSpecimen Inc. adjourned its 2025 Annual Meeting of Stockholders due to a lack of quorum, rescheduling it for January 23, 2026.

iSpecimen Inc. has entered into a $2 million consulting agreement with IR Agency LLC for marketing, advertising, and investor communications services.

iSpecimen Inc. has raised $5.5 million through a private placement of Series C Convertible Non-Voting Preferred Stock to accredited investors.

iSpecimen Inc. announced it has regained full compliance with Nasdaq's continued listing requirements, resolving previous non-compliance issues.

iSpecimen Inc. received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day period to regain compliance.

iSpecimen Inc. announced the appointment of Katharyn Field as Chief Executive Officer and Arphing Lee as an independent director, following the resignation of Robert Bradley Lim.

iSpecimen Inc. stockholders approved a reverse stock split, increased authorized shares, and cleared the way for significant capital raising activities.

iSpecimen Inc. announced an update on its strategic initiative to build an up to $200 million corporate treasury reserve based on the Solana blockchain, engaging with crypto companies for various digital asset opportunities.

iSpecimen Inc. announced the successful completion of Milestone 1 in its digital transformation program, laying the foundation for enhanced operational efficiency and scalability.

iSpecimen Inc. announces a strategic initiative to establish an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem.

iSpecimen Inc. completed a private placement, raising approximately $1.75 million by issuing common stock and pre-funded warrants to accredited investors.

iSpecimen Inc. announced the pricing and closing of an underwritten public offering, raising approximately $4 million in gross proceeds through the sale of 5,714,283 shares of common stock or pre-funded warrants at $0.70 per share.

iSpecimen Inc. has amended its bylaws to reduce the quorum requirement for shareholder meetings from a majority to 34% of voting power, effective July 9, 2025.

iSpecimen Inc. reported the immediate resignations of two directors, Richard J. Paolone and John L. Brooks III, and the appointment of Anthony Lau to its Board of Directors and key committees.

iSpecimen Inc. has received a notice from Nasdaq indicating non-compliance with listing rules due to its stockholders' equity falling below the required $2.5 million minimum, initiating a 45-day period to submit a compliance plan.